Company: VERA
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029969
Chunk: 141

Company: Vera Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 141
---
 losses on marketable securities

    142

    251

    Comprehensive loss
     
    $
    (152,006
    )
     
    $
    (95,739
    )

    Net loss per share attributable to common stockholders, basic and diluted
     
    $
    (2.75
    )
     
    $
    (2.25
    )

    Weighted-average shares used in computing net loss per share   attributable to common stockholders, basic and diluted

    55,326,680

    42,707,072

The accompanying notes are an integral part of these financial statements.

104

VERA THERAPEUTICS, INC. 

Statements of Stockholders’ Equity

(in thousands, except share amounts) 

    Class A Common Stock

    Additional Paid-in

    Accumulated Other Comprehensive

    Accumulated

    TotalStockholders’

    Shares

    Amount

    Capital

    Income (Loss)

    Deficit

    Equity

    Balances as of December 31, 2022

    27,800,861

    $
    28

    $
    290,216

    $
    (224
    )
     
    $
    (213,112
    )
     
    $
    76,908

    Issuance of common stock from underwritten follow-on offering, net of offering costs

    16,428,572

    16

    107,727

    —

    —

    107,743

    Issuance of common stock pursuant to exercise of options

    111,927

    —

    781

    —

    —

    781

    Issuance of common stock upon vesting of restricted stock units

    66,321

    —

    —

    —

    —

    —

    Issuance of common stock pursuant to employee stock purchase plan

    44,480

    —

    275

    —

    —

    275

    Stock-based compensation

    —

    —

    11,493

    —

    —

    11,493

    Unrealized gain on marketable securities

    —

    —

    —

    475

    —

    475

    Net loss

    —

    —

    —

    —

    (95,990
    )

    (95,990
    )

    Balances as of December 31, 2023